Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Identifieur interne : 003117 ( Main/Exploration ); précédent : 003116; suivant : 003118Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Auteurs : Mark A. Boyd [Australie] ; Cecilia L. Moore [Australie] ; Jean-Michel Molina [France] ; Robin Wood [Afrique du Sud] ; Juan S. Madero [Mexique] ; Marcelo Wolff [Chili] ; Kiat Ruxrungtham [Thaïlande] ; Marcelo Losso [Argentine] ; Boris Renjifo [États-Unis] ; Hedy Teppler [États-Unis] ; Anthony D. Kelleher [Australie] ; Janaki Amin [Australie] ; Sean Emery [Australie] ; David A. Cooper [Australie]Source :
- The lancet. HIV [ 2352-3018 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (usage thérapeutique), Association de médicaments, Australie-Méridionale, Charge virale (), Didéoxynucléosides (usage thérapeutique), Femelle, Humains, Infections à VIH (psychologie), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Jeune adulte, Lamivudine (usage thérapeutique), Lopinavir (usage thérapeutique), Mâle, Observance du traitement médicamenteux, Ritonavir (usage thérapeutique), Résistance virale aux médicaments, Résultat thérapeutique, Ténofovir (usage thérapeutique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (physiologie).
- MESH :
- génétique : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- physiologie : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- psychologie : Infections à VIH.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH, Didéoxynucléosides, Lamivudine, Lopinavir, Ritonavir, Ténofovir.
- virologie : Infections à VIH.
- Adulte, Adulte d'âge moyen, Association de médicaments, Australie-Méridionale, Charge virale, Femelle, Humains, Jeune adulte, Mâle, Observance du traitement médicamenteux, Résistance virale aux médicaments, Résultat thérapeutique, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (therapeutic use), Dideoxynucleosides (therapeutic use), Drug Resistance, Viral, Drug Therapy, Combination, Female, HIV Infections (drug therapy), HIV Infections (psychology), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), HIV-1 (isolation & purification), HIV-1 (physiology), Humans, Lamivudine (therapeutic use), Lopinavir (therapeutic use), Male, Medication Adherence, Middle Aged, Ritonavir (therapeutic use), South Australia, Tenofovir (therapeutic use), Treatment Outcome, Viral Load (drug effects), Young Adult.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Dideoxynucleosides, Lamivudine, Lopinavir, Ritonavir, Tenofovir.
- geographic : South Australia.
- drug effects : HIV-1, Viral Load.
- drug therapy : HIV Infections.
- genetics : HIV-1.
- isolation & purification : HIV-1.
- physiology : HIV-1.
- psychology : HIV Infections.
- virology : HIV Infections.
- Adult, Drug Resistance, Viral, Drug Therapy, Combination, Female, Humans, Male, Medication Adherence, Middle Aged, Treatment Outcome, Young Adult.
Abstract
WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART with ritonavir-boosted lopinavir and raltegravir (raltegravir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and two or three NtRTIs (NtRTI-group) in participants with virological failure composed of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs. We report the relation of baseline virological resistance with virological failure and emergent resistance on study.
DOI: 10.1016/S2352-3018(14)00061-7
PubMed: 26424460
Affiliations:
- Afrique du Sud, Argentine, Australie, Chili, France, Mexique, Thaïlande, États-Unis
- Illinois, New Jersey, Île-de-France
- Paris
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003039
- to stream PubMed, to step Curation: 002F58
- to stream PubMed, to step Checkpoint: 002F58
- to stream Ncbi, to step Merge: 002B51
- to stream Ncbi, to step Curation: 002B51
- to stream Ncbi, to step Checkpoint: 002B51
- to stream Main, to step Merge: 003118
- to stream Main, to step Curation: 003117
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.</title><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia. Electronic address: mboyd@kirby.unsw.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Saint-Louis, Department of Clinical Infectious Diseases, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospital Saint-Louis, Department of Clinical Infectious Diseases, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name><affiliation wicri:level="1"><nlm:affiliation>Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town</wicri:regionArea><wicri:noRegion>University of Cape Town</wicri:noRegion></affiliation></author><author><name sortKey="Madero, Juan S" sort="Madero, Juan S" uniqKey="Madero J" first="Juan S" last="Madero">Juan S. Madero</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Nacional de Ciencias Medicas y Nutricion (Salvador Zubirán), Department of Infectious Diseases, Mexico D F, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Nacional de Ciencias Medicas y Nutricion (Salvador Zubirán), Department of Infectious Diseases, Mexico D F</wicri:regionArea><wicri:noRegion>Mexico D F</wicri:noRegion></affiliation></author><author><name sortKey="Wolff, Marcelo" sort="Wolff, Marcelo" uniqKey="Wolff M" first="Marcelo" last="Wolff">Marcelo Wolff</name><affiliation wicri:level="1"><nlm:affiliation>Hospital San Borja-Arriaran, University of Chile, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Hospital San Borja-Arriaran, University of Chile, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation wicri:level="1"><nlm:affiliation>Chulalongkorn University; HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, 10330, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Chulalongkorn University; HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, 10330</wicri:regionArea><wicri:noRegion>10330</wicri:noRegion></affiliation></author><author><name sortKey="Losso, Marcelo" sort="Losso, Marcelo" uniqKey="Losso M" first="Marcelo" last="Losso">Marcelo Losso</name><affiliation wicri:level="1"><nlm:affiliation>Hospital J M Ramos Mejía, Servicio de Immunocompromatidos, Pabellon de Clinica, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Hospital J M Ramos Mejía, Servicio de Immunocompromatidos, Pabellon de Clinica, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name><affiliation wicri:level="2"><nlm:affiliation>Global Medical Affairs, Virology, Global Pharmaceutical Research & Development, AbbVie Inc, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Medical Affairs, Virology, Global Pharmaceutical Research & Development, AbbVie Inc, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation wicri:level="2"><nlm:affiliation>Merck Clinical Research-Infectious Diseases, Merck, Whitehouse Station, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck Clinical Research-Infectious Diseases, Merck, Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kelleher, Anthony D" sort="Kelleher, Anthony D" uniqKey="Kelleher A" first="Anthony D" last="Kelleher">Anthony D. Kelleher</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26424460</idno><idno type="pmid">26424460</idno><idno type="doi">10.1016/S2352-3018(14)00061-7</idno><idno type="wicri:Area/PubMed/Corpus">003039</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003039</idno><idno type="wicri:Area/PubMed/Curation">002F58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F58</idno><idno type="wicri:Area/PubMed/Checkpoint">002F58</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F58</idno><idno type="wicri:Area/Ncbi/Merge">002B51</idno><idno type="wicri:Area/Ncbi/Curation">002B51</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B51</idno><idno type="wicri:Area/Main/Merge">003118</idno><idno type="wicri:Area/Main/Curation">003117</idno><idno type="wicri:Area/Main/Exploration">003117</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.</title><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia. Electronic address: mboyd@kirby.unsw.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Saint-Louis, Department of Clinical Infectious Diseases, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospital Saint-Louis, Department of Clinical Infectious Diseases, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name><affiliation wicri:level="1"><nlm:affiliation>Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town</wicri:regionArea><wicri:noRegion>University of Cape Town</wicri:noRegion></affiliation></author><author><name sortKey="Madero, Juan S" sort="Madero, Juan S" uniqKey="Madero J" first="Juan S" last="Madero">Juan S. Madero</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Nacional de Ciencias Medicas y Nutricion (Salvador Zubirán), Department of Infectious Diseases, Mexico D F, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Nacional de Ciencias Medicas y Nutricion (Salvador Zubirán), Department of Infectious Diseases, Mexico D F</wicri:regionArea><wicri:noRegion>Mexico D F</wicri:noRegion></affiliation></author><author><name sortKey="Wolff, Marcelo" sort="Wolff, Marcelo" uniqKey="Wolff M" first="Marcelo" last="Wolff">Marcelo Wolff</name><affiliation wicri:level="1"><nlm:affiliation>Hospital San Borja-Arriaran, University of Chile, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Hospital San Borja-Arriaran, University of Chile, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation wicri:level="1"><nlm:affiliation>Chulalongkorn University; HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, 10330, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Chulalongkorn University; HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, 10330</wicri:regionArea><wicri:noRegion>10330</wicri:noRegion></affiliation></author><author><name sortKey="Losso, Marcelo" sort="Losso, Marcelo" uniqKey="Losso M" first="Marcelo" last="Losso">Marcelo Losso</name><affiliation wicri:level="1"><nlm:affiliation>Hospital J M Ramos Mejía, Servicio de Immunocompromatidos, Pabellon de Clinica, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Hospital J M Ramos Mejía, Servicio de Immunocompromatidos, Pabellon de Clinica, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name><affiliation wicri:level="2"><nlm:affiliation>Global Medical Affairs, Virology, Global Pharmaceutical Research & Development, AbbVie Inc, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Medical Affairs, Virology, Global Pharmaceutical Research & Development, AbbVie Inc, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation wicri:level="2"><nlm:affiliation>Merck Clinical Research-Infectious Diseases, Merck, Whitehouse Station, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck Clinical Research-Infectious Diseases, Merck, Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kelleher, Anthony D" sort="Kelleher, Anthony D" uniqKey="Kelleher A" first="Anthony D" last="Kelleher">Anthony D. Kelleher</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute for Infection and Immunity in Society, UNSW Medicine, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author></analytic><series><title level="j">The lancet. HIV</title><idno type="eISSN">2352-3018</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>Dideoxynucleosides (therapeutic use)</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (psychology)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>HIV-1 (isolation & purification)</term><term>HIV-1 (physiology)</term><term>Humans</term><term>Lamivudine (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Ritonavir (therapeutic use)</term><term>South Australia</term><term>Tenofovir (therapeutic use)</term><term>Treatment Outcome</term><term>Viral Load (drug effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (usage thérapeutique)</term><term>Association de médicaments</term><term>Australie-Méridionale</term><term>Charge virale ()</term><term>Didéoxynucléosides (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (psychologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Jeune adulte</term><term>Lamivudine (usage thérapeutique)</term><term>Lopinavir (usage thérapeutique)</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>Ritonavir (usage thérapeutique)</term><term>Résistance virale aux médicaments</term><term>Résultat thérapeutique</term><term>Ténofovir (usage thérapeutique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Dideoxynucleosides</term><term>Lamivudine</term><term>Lopinavir</term><term>Ritonavir</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>South Australia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Didéoxynucléosides</term><term>Lamivudine</term><term>Lopinavir</term><term>Ritonavir</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Australie-Méridionale</term><term>Charge virale</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>Résistance virale aux médicaments</term><term>Résultat thérapeutique</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART with ritonavir-boosted lopinavir and raltegravir (raltegravir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and two or three NtRTIs (NtRTI-group) in participants with virological failure composed of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs. We report the relation of baseline virological resistance with virological failure and emergent resistance on study.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Argentine</li><li>Australie</li><li>Chili</li><li>France</li><li>Mexique</li><li>Thaïlande</li><li>États-Unis</li></country><region><li>Illinois</li><li>New Jersey</li><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name></noRegion><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><name sortKey="Kelleher, Anthony D" sort="Kelleher, Anthony D" uniqKey="Kelleher A" first="Anthony D" last="Kelleher">Anthony D. Kelleher</name><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name></country><country name="France"><region name="Île-de-France"><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name></region></country><country name="Afrique du Sud"><noRegion><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name></noRegion></country><country name="Mexique"><noRegion><name sortKey="Madero, Juan S" sort="Madero, Juan S" uniqKey="Madero J" first="Juan S" last="Madero">Juan S. Madero</name></noRegion></country><country name="Chili"><noRegion><name sortKey="Wolff, Marcelo" sort="Wolff, Marcelo" uniqKey="Wolff M" first="Marcelo" last="Wolff">Marcelo Wolff</name></noRegion></country><country name="Thaïlande"><noRegion><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name></noRegion></country><country name="Argentine"><noRegion><name sortKey="Losso, Marcelo" sort="Losso, Marcelo" uniqKey="Losso M" first="Marcelo" last="Losso">Marcelo Losso</name></noRegion></country><country name="États-Unis"><region name="Illinois"><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name></region><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26424460
|texte= Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26424460" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |